OREANDA-NEWS   A flu vaccine with four times the antigen of a standard vaccine could significantly reduce the risk of hospitalization among especially vulnerable seniors, a large, random clinical trial has found.

Vaccines typically don’t work very well in older people—a problem because the flu can lead to serious respiratory infections in frail patients such as elderly nursing home residents.

“…the rate of hospitalization for any reason, respiratory or otherwise, was significantly lower in the high-dose group…”

While a prior study showed that older individuals could respond better to the high-dose vaccine, it focused on relatively healthy older adults, says lead author Stefan Gravenstein, professor at both the Warren Alpert Medical School and the School of Public Health at Brown University.

“It still needed to be established that it would help even the frailest folks, like those who reside in nursing homes. In our study, a quarter of the sample was over 90. So we asked if the high-dose vaccine also would work better than regular-dose vaccine in the population we consider least able to respond. This paper says yes, it can.”

The study compared hospitalization rates among more than 38,000 residents of 823 nursing homes in 38 states during the 2013-14 flu season based on Medicare claims data. Just under half the homes, 409 to be exact, administered the high-dose vaccine while the other 414 provided a standard dose.

In the end, the hospitalization rate for respiratory illnesses among high-dose patients was 3.4 percent compared to 3.8 percent among standard-dose patients over the six months after vaccination. Statistical analysis revealed that the relative risk of hospitalization for respiratory illness was 12.7 percent lower for the high-dose group.

Moreover, the rate of hospitalization for any reason, respiratory or otherwise, was significantly lower in the high-dose group as well. For every 69 people given the high-dose vaccine vs. the standard-dose vaccine, one more person stayed out of the hospital during the flu season.

“Respiratory illness as the primary reason for hospitalization accounted for only about a third of the reduction in hospitalization that we measured,” says Gravenstein.

For many patients, the vaccine appeared to help prevent hospitalization for other problems also, including cardiovascular symptoms.

Nope, the flu vaccine won’t give you the flu

Gravenstein says the finding of a significant reduction in hospitalizations was particularly notable because the predominant flu strain during the 2013-14 season, A/H1N1pdm, was believed to be less virulent in older people who had spent a long lifetime building up immunity to similar strains.

“That there was differential protection in this context both underlines the potential importance of even low-virulence or less transmissible strains to older populations and the fact that vaccines may afford relevant effectiveness among frail older persons even when A/H1N1 predominates,” the authors write.

The study did not find a significant difference in the rate of death. Researchers speculate that while the standard-dose vaccine might not have been strong enough to stave off illness entirely, it may still have been sufficient to prevent deaths in combination with hospital care.

But a significant reduction in hospitalizations can still be a benefit, Gravenstein says, even though the high-dose vaccine is more expensive than the standard-dose vaccine. Especially for older, frail patients, reducing otherwise necessary trips to the hospital can maintain a higher quality of life.

Ultimately, Gravenstein says, the study should provide nursing home leadership with useful information to consider as they plan for future flu seasons.

Fewer deaths in nursing homes when flu shots work

Sanofi Pasteur, the company that makes the high-dose vaccine, supplied it and provided funding for the study, but had no role in its design or the collection, analysis, or interpretation of the data.

The research appears in the journal Lancet Respiratory Medicine. Additional researchers who contributed to the research are from Brown, the University of Ottawa, and Insight Therapeutics.